To include your compound in the COVID-19 Resource Center, submit it here.
The double-blind, U.S. Phase III HLD-200-108 trial in 161 patients ages 6-12 with ADHD in a naturalistic setting showed that once-daily oral
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury